FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023459069> ?p ?o ?g. }

• W2023459069 endingPage "721" @default.
• W2023459069 startingPage "711" @default.
• W2023459069 abstract "Retigabine (D-23129), an N-2-amino-4-(4-fluorobenzylamino)phenylcarbamine acid ethyl ester, is a novel antiepileptic drug which is currently in phase II clinical development. This drug undergoes N-glucuronidation. We aimed to identify the principal enzymes involved in the N-glucuronidation pathway of retigabine and compared our findings with those obtained from human liver (a pool of 30 donors) and kidney microsomes (a pool of 3 donors) and with results from a human absorption, distribution, metabolism, and excretion study upon administration of 200 microCi of [(14)C]-D-23129. Essentially, microsomal assays with UGT1A1 produced only one of the 2 N-glucuronides, whereas UGT1A9 is capable of forming both N-glucuronides. The rates of metabolism for UGT1A9, human liver microsomes, and UGT1A1 were 200, 100, and 100 pmol N-glucuronide per minute per milligram of protein, respectively. At the 50 micromol/L uridine diphosphate glucoronic acid (UDPGA) concentration, UGT1A4 also catalyzed the N-glucuronidation of retigabine, the rates being approximately 5 and 6 pmol/(min.mg protein). With UGT1A9, the production of metabolites 1 and 2 proceeded at a K(m) of 38+/-25 and 45+/-15 micromol/L, whereas the K(m) for retigabine N-glucuronidation by human liver microsomal fractions was 145+/-39 micromol/L. Furthermore, a V(max) of 1.2+/-0.3 (nmol/[min.mg protein]) was estimated for human liver microsomes (4 individual donors). We investigated the potential for drug-drug interaction using the antiepileptic drugs valproic acid, lamotrigine, the tricyclic antidepressant imipramine, and the anesthetic propofol. These are commonly used medications and are extensively glucuronidated. No potential for drug-drug interactions was found at clinically relevant concentrations (when assayed with human liver microsomes or UGT1A9 enzyme preparations). Notably, the biosynthesis of retigabine-N-glucuronides was not inhibited in human liver microsomal assays in the presence of 330 micromol/L bilirubin, and glucuronidation of retigabine was also observed with microsomal preparations from human kidney and Crigler-Najjar type II liver. This suggests that lack of a particular UDP-glucuronosyltransferase (UGT) isoform (eg, UGT1A1 in kidney) or functional loss of an entire UGT1A gene does not completely abolish disposal of the drug. Finally, chromatographic separations of extracts from microsomal assays and human urine of volunteers receiving a single dose of (14)C-retigabine provided clear evidence for the presence of the 2 N-glucuronides known to be produced by UGT1A9. We therefore suggest N-glucuronidation of retigabine to be of importance in the metabolic clearance of this drug." @default.
• W2023459069 created "2016-06-24" @default.
• W2023459069 creator A5000991422 @default.
• W2023459069 creator A5014477849 @default.
• W2023459069 creator A5070110721 @default.
• W2023459069 creator A5083022088 @default.
• W2023459069 creator A5089631740 @default.
• W2023459069 date "2006-06-01" @default.
• W2023459069 modified "2023-10-14" @default.
• W2023459069 title "N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II" @default.
• W2023459069 cites W1577063795 @default.
• W2023459069 cites W1700971463 @default.
• W2023459069 cites W1969680395 @default.
• W2023459069 cites W1981331912 @default.
• W2023459069 cites W1985901897 @default.
• W2023459069 cites W1987357626 @default.
• W2023459069 cites W1996892862 @default.
• W2023459069 cites W1997537641 @default.
• W2023459069 cites W2002583826 @default.
• W2023459069 cites W2018590444 @default.
• W2023459069 cites W2055766784 @default.
• W2023459069 cites W2070885936 @default.
• W2023459069 cites W2094892570 @default.
• W2023459069 cites W2140741881 @default.
• W2023459069 cites W2158225751 @default.
• W2023459069 cites W2171670007 @default.
• W2023459069 cites W338512271 @default.
• W2023459069 doi "https://doi.org/10.1016/j.metabol.2006.01.006" @default.
• W2023459069 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16713428" @default.
• W2023459069 hasPublicationYear "2006" @default.
• W2023459069 type Work @default.
• W2023459069 sameAs 2023459069 @default.
• W2023459069 citedByCount "54" @default.
• W2023459069 countsByYear W20234590692012 @default.
• W2023459069 countsByYear W20234590692013 @default.
• W2023459069 countsByYear W20234590692014 @default.
• W2023459069 countsByYear W20234590692015 @default.
• W2023459069 countsByYear W20234590692016 @default.
• W2023459069 countsByYear W20234590692018 @default.
• W2023459069 countsByYear W20234590692019 @default.
• W2023459069 countsByYear W20234590692020 @default.
• W2023459069 countsByYear W20234590692021 @default.
• W2023459069 countsByYear W20234590692022 @default.
• W2023459069 countsByYear W20234590692023 @default.
• W2023459069 crossrefType "journal-article" @default.
• W2023459069 hasAuthorship W2023459069A5000991422 @default.
• W2023459069 hasAuthorship W2023459069A5014477849 @default.
• W2023459069 hasAuthorship W2023459069A5070110721 @default.
• W2023459069 hasAuthorship W2023459069A5083022088 @default.
• W2023459069 hasAuthorship W2023459069A5089631740 @default.
• W2023459069 hasConcept C181199279 @default.
• W2023459069 hasConcept C185592680 @default.
• W2023459069 hasConcept C2777469378 @default.
• W2023459069 hasConcept C2779907587 @default.
• W2023459069 hasConcept C2781278898 @default.
• W2023459069 hasConcept C55493867 @default.
• W2023459069 hasConcept C62231903 @default.
• W2023459069 hasConcept C71924100 @default.
• W2023459069 hasConcept C87644729 @default.
• W2023459069 hasConcept C89311334 @default.
• W2023459069 hasConcept C98274493 @default.
• W2023459069 hasConceptScore W2023459069C181199279 @default.
• W2023459069 hasConceptScore W2023459069C185592680 @default.
• W2023459069 hasConceptScore W2023459069C2777469378 @default.
• W2023459069 hasConceptScore W2023459069C2779907587 @default.
• W2023459069 hasConceptScore W2023459069C2781278898 @default.
• W2023459069 hasConceptScore W2023459069C55493867 @default.
• W2023459069 hasConceptScore W2023459069C62231903 @default.
• W2023459069 hasConceptScore W2023459069C71924100 @default.
• W2023459069 hasConceptScore W2023459069C87644729 @default.
• W2023459069 hasConceptScore W2023459069C89311334 @default.
• W2023459069 hasConceptScore W2023459069C98274493 @default.
• W2023459069 hasIssue "6" @default.
• W2023459069 hasLocation W20234590691 @default.
• W2023459069 hasLocation W20234590692 @default.
• W2023459069 hasOpenAccess W2023459069 @default.
• W2023459069 hasPrimaryLocation W20234590691 @default.
• W2023459069 hasRelatedWork W1710528628 @default.
• W2023459069 hasRelatedWork W2054706176 @default.
• W2023459069 hasRelatedWork W2058870475 @default.
• W2023459069 hasRelatedWork W2095892621 @default.
• W2023459069 hasRelatedWork W2105026769 @default.
• W2023459069 hasRelatedWork W2127974033 @default.
• W2023459069 hasRelatedWork W2136434035 @default.
• W2023459069 hasRelatedWork W2405358853 @default.
• W2023459069 hasRelatedWork W2614007565 @default.
• W2023459069 hasRelatedWork W3124413224 @default.
• W2023459069 hasVolume "55" @default.
• W2023459069 isParatext "false" @default.
• W2023459069 isRetracted "false" @default.
• W2023459069 magId "2023459069" @default.
• W2023459069 workType "article" @default.